MicroRNAs in osteosarcoma

Clinica Chimica Acta

Volumn 444, Issue , 2015, Pages 9-17

  Zhang, Jian ^a   Yan, Yi Guo ^a   Wang, Cheng ^a   Zhang, Shu Jun ^a   Yu, Xiao Hua ^a   Wang, Wen Jun ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Chemoresistance; MiRNAs; Notch; OS; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; CIRCULATING MICRORNA; MICRORNA; MICRORNA 125B; MICRORNA 133B; MICRORNA 142 3P; MICRORNA 143; MICRORNA 145; MICRORNA 183; MICRORNA 200B; MICRORNA 200C; MICRORNA 206; MICRORNA 320; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANTINEOPLASTIC ACTIVITY; BIOGENESIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; METASTASIS POTENTIAL; NONHUMAN; OSTEOSARCOMA; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; REVIEW; SIGNAL TRANSDUCTION; GENE EXPRESSION PROFILING; GENETICS;

BIOMARKERS; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; OSTEOSARCOMA;

EID: 84922697089     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.01.025     Document Type: Review

References (113)

1. He J.P., Hao Y., Wang X.L., et al. Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev 2014, 15:5967-5976.
2. Zhou W., Hao M., Du X., et al. Advances in targeted therapy for osteosarcoma. Discov Med 2014, 17:301-307.
3. Luetke A., Meyers P.A., Lewis I., et al. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 2014, 40:523-532.
4. Ell B., Kang Y. MicroRNAs as regulators of bone homeostasis and bone metastasis. Bonekey Rep 2014, 3:549.
5. Bottai G., Pasculli B., Calin G.A., et al. Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opin Biol Ther 2014, 1-17.
6. Adams B.D., Kasinski A.L., Slack F.J. Aberrant regulation and function of MicroRNAs in cancer. Curr Biol 2014, 24:R762-R776.
7. Nugent M. MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res 2014, 6:15-25.
8. Miao J., Wu S., Peng Z., et al. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 2013, 34:2093-2098.
9. Bronze-da-Rocha E. MicroRNAs expression profiles in cardiovascular diseases. Biomed Res Int 2014, 2014:985408.
10. Ozsolak F., Poling L.L., Wang Z., et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008, 22:3172-3183.
11. Vickers K.C., Remaley A.T. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol Diabetes Obes 2010, 17:150-155.
12. Lee Y., Ahn C., Han J., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425:415-419.
13. Westholm J.O., Lai E.C. Mirtrons: microRNA biogenesis via splicing. Biochimie 2011, 93:1897-1904.
14. Ladewig E., Okamura K., Flynt A.S., et al. Discovery of hundreds of mirtrons in mouse and human small RNA data. Genome Res 2012, 22:1634-1645.
15. Yao J., Wang Y., Wang W., et al. Solexa sequencing analysis of chicken pre-adipocyte microRNAs. Biosci Biotechnol Biochem 2011, 75:54-61.
16. Patanun O., Lertpanyasampatha M., Sojikul P., et al. Computational identification of microRNAs and their targets in cassava (Manihot esculenta Crantz). Mol Biotechnol 2013, 53:257-269.
17. Foulkes W.D., Priest J.R., Duchaine T.F. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 2014, 14:662-672.
18. Yang J.S., Maurin T., Lai E.C. Functional parameters of Dicer-independent microRNA biogenesis. RNA 2012, 18:945-957.
19. Marasovic M., Zocco M., Halic M. Argonaute and Triman generate dicer-independent priRNAs and mature siRNAs to initiate heterochromatin formation. Mol Cell 2013, 52:173-183.
20. Stappert L., Roese-Koerner B., Brustle O. The role of microRNAs in human neural stem cells, neuronal differentiation and subtype specification. Cell Tissue Res 2015, 359:47-64.
21. Forman J.J., Legesse-Miller A., Coller H.A. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci U S A 2008, 105:14879-14884.
22. Gayral M., Jo S., Hanoun N., et al. MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol 2014, 20:11199-11209.
23. Grimson A., Farh K.K., Johnston W.K., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007, 27:91-105.
24. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
25. Hu H., Zhang Y., Cai X.H., et al. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett 2012, 4:1037-1042.
26. Dai N., Zhong Z.Y., Cun Y.P., et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma 2013, 60:384-394.
27. Won K.Y., Kim Y.W., Kim H.S., et al. MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum Pathol 2013, 44:1648-1655.
28. Lauvrak S.U., Munthe E., Kresse S.H., et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer 2013, 109:2228-2236.
29. Namlos H.M., Meza-Zepeda L.A., Baroy T., et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 2012, 7:e48086.
30. Duan Z., Choy E., Harmon D., et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 2011, 10:1337-1345.
31. Arabi L., Gsponer J.R., Smida J., et al. Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences. Genes Cancer 2014, 5:56-63.
32. Lulla R.R., Costa F.F., Bischof J.M., et al. Identification of differentially expressed MicroRNAs in osteosarcoma. Sarcoma 2011, 2011:732690.
33. Diao C.Y., Guo H.B., Ouyang Y.R., et al. Screening for metastatic osteosarcoma biomarkers with a DNA microarray. Asian Pac J Cancer Prev 2014, 15:1817-1822.
34. Gougelet A., Pissaloux D., Besse A., et al. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 2011, 129:680-690.
35. Tian Q., Jia J., Ling S., et al. A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol 2014, 40:67-72.
36. Zhang C., Yao C., Li H., et al. Combined elevation of microRNA-196a and microRNA-196b in sera predicts unfavorable prognosis in patients with osteosarcomas. Int J Mol Sci 2014, 15:6544-6555.
37. Ma W., Zhang X., Chai J., et al. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumour Biol 2014, 35:12467-12472.
38. Ouyang L., Liu P., Yang S., et al. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. Med Oncol 2013, 30:340.
39. Yuan J., Chen L., Chen X., et al. Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res 2012, 40:2090-2097.
40. Fei D., Li Y., Zhao D., et al. Serum miR-9 as a prognostic biomarker in patients with osteosarcoma. J Int Med Res 2014, 42:932-937.
41. Zhang C., Yao C., Li H., et al. Serum levels of microRNA-133b and microRNA-206 expression predict prognosis in patients with osteosarcoma. Int J Clin Exp Pathol 2014, 7:4194-4203.
42. Soderstrom M., Palokangas T., Vahlberg T., et al. Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas. APMIS 2010, 118:769-776.
43. Machado I., Navarro S., Giner F., et al. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors. Virchows Arch 2010, 457:87-89.
44. Chen Q.Y., Xu W., Jiao D.M., et al. Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro. Mol Cell Biochem 2013, 377:207-218.
45. Zhang J., Zuo J., Lei M., et al. Ezrin promotes invasion and migration of the MG63 osteosarcoma cell. Chin Med J (Engl) 2014, 127:1954-1959.
46. Lo Vasco V.R., Leopizzi M., Puggioni C., et al. Ezrin silencing remodulates the expression of phosphoinositide-specific phospholipase C enzymes in human osteosarcoma cell lines. J Cell Commun Signal 2014, 8:219-229.
47. Bulut G., Hong S.H., Chen K., et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012, 31:269-281.
48. Mu Y., Zhang H., Che L., et al. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol 2014, 31:821.
49. Zhao H., Guo M., Zhao G., et al. miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med 2012, 30:1013-1020.
50. Zhu J., Feng Y., Ke Z., et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol 2012, 180:2440-2451.
51. Ognjanovic S., Olivier M., Bergemann T.L., et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer 2012, 118:1387-1396.
52. Osumi T., Miharu M., Fuchimoto Y., et al. The germline TP53 mutation c.722 C>T promotes bone and liver tumorigenesis at a young age. Pediatr Blood Cancer 2012, 59:1332-1333.
53. Sakurai N., Iwamoto S., Miura Y., et al. Novel p53 splicing site mutation in Li-Fraumeni-like syndrome with osteosarcoma. Pediatr Int 2013, 55:107-111.
54. He C., Xiong J., Xu X., et al. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 2009, 388:35-40.
55. Tian Y., Zhang Y.Z., Chen W. MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells. Biosci Rep 2014, 34:281-286.
56. Wu X., Zhong D., Gao Q., et al. MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether a go-go 1 expression. Int J Med Sci 2013, 10:676-682.
57. Martin J.W., Chilton-MacNeill S., Koti M., et al. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One 2014, 9:e95843.
58. van der Deen M., Taipaleenmaki H., Zhang Y., et al. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem 2013, 288:21307-21319.
59. Creighton C.J., Fountain M.D., Yu Z., et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 2010, 70:1906-1915.
60. Zhu L.B., Jiang J., Zhu X.P., et al. Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K/Akt/NF-kappaB signaling pathway. Int J Clin Exp Pathol 2014, 7:3984-3991.
61. Hou C.H., Lin F.L., Tong K.B., et al. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol 2014, 89:453-463.
62. Li G., Cai M., Fu D., et al. Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem 2012, 30:1481-1490.
63. Li J., You T., Jing J. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway. Cell Prolif 2014, 47:152-160.
64. Nakanishi A., Wada Y., Kitagishi Y., et al. Link between PI3K/AKT/PTEN pathway and NOX Proteinin Diseases. Aging Dis 2014, 5:203-211.
65. Gao Y., Luo L.H., Li S., et al. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun 2014, 444:230-234.
66. Shen L., Chen X.D., Zhang Y.H. MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN. Tumour Biol 2014, 35:2069-2074.
67. Zhao G., Cai C., Yang T., et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013, 8:e53906.
68. Bertrand F.E., McCubrey J.A., Angus C.W., et al. NOTCH and PTEN in prostate cancer. Adv Biol Regul 2014, 56:51-65.
69. Hughes D.P. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res 2009, 152:479-496.
70. Li Y., Zhang J., Zhang L., et al. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis 2013, 34:1601-1610.
71. Yan K., Gao J., Yang T., et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 2012, 7:e33778.
72. Bae Y., Yang T., Zeng H.C., et al. miRNA-34c regulates Notch signaling during bone development. Hum Mol Genet 2012, 21:2991-3000.
73. Zhao H., Li M., Li L., et al. MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS One 2013, 8:e83571.
74. Novello C., Pazzaglia L., Cingolani C., et al. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol 2013, 42:667-675.
75. Bao Y.P., Yi Y., Peng L.L., et al. Roles of microRNA-206 in osteosarcoma pathogenesis and progression. Asian Pac J Cancer Prev 2013, 14:3751-3755.
76. Zhang K., Zhang Y., Ren K., et al. MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression. Oncol Rep 2014, 32:2143-2149.
77. Sun Z., Zhang T., Hong H., et al. miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2. Mol Cell Biochem 2014, 397:277-283.
78. Song L., Yang J., Duan P., et al. MicroRNA-24 inhibits osteosarcoma cell proliferation both in vitro and in vivo by targeting LPAATbeta. Arch Biochem Biophys 2013, 535:128-135.
79. Jianwei Z., Fan L., Xiancheng L., Sun Z., Zhang T., Hong H. MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol 2013, 34:3331-3337.
80. Pan W., Wang H., Jianwei R., Sun Z., Zhang T., Hong H. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem 2014, 33:402-412.
81. Xu Z., Wang T. miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. Biochem Biophys Res Commun 2014, 449:190-195.
82. Alameddine R.S., Hamieh L., Shamseddine A. From sprouting angiogenesis to erythrocytes generation by cancer stem cells: evolving concepts in tumor microcirculation. Biomed Res Int 2014, 2014:986768.
83. Di Fiore R., Drago-Ferrante R., Pentimalli F., et al. MicroRNA-29b-1 impairs in vitro cell proliferation, selfrenewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol 2014, 45:2013-2023.
84. Hong Q., Fang J., Pang Y., et al. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol 2014, 31:37.
85. D'Adamo D.R. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011, 38(Suppl. 3):S19-S29.
86. Xu M., Jin H., Xu C.X., et al. MiR-34c inhibits osteosarcoma metastasis and chemoresistance. Med Oncol 2014, 31:972.
87. Zhou Y., Huang Z., Wu S., et al. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 2014, 33:12.
88. Song B., Wang Y., Titmus M.A., et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010, 9:96.
89. Song B., Wang Y., Xi Y., et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
90. O'Farrill J.S., Gordon N. Autophagy in osteosarcoma. Adv Exp Med Biol 2014, 804:147-160.
91. He H., Ni J., Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014, 7:1352-1362.
92. Chang Z., Huo L., Li K., et al. Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. ScientificWorldJournal 2014, 2014:794756.
93. Li X., Wang S., Chen Y., et al. miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biol 2014, 35:6021-6028.
94. Chen L., Jiang K., Jiang H., et al. miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Exp Ther Med 2014, 8:527-532.
95. Fujiwara T., Katsuda T., Hagiwara K., et al. Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells 2014, 32:959-973.
96. Xu G., Wang J., Jia Y., et al. MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1. Cell Physiol Biochem 2014, 33:1329-1339.
97. Wang J., Xu G., Shen F., et al. miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. Tumour Biol 2014, 35:4859-4865.
98. Cheng C., Chen Z.Q., Shi X.T. MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol 2014, 35:4177-4183.
99. Zhou X., Wei M., Wang W. MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. Biochem Biophys Res Commun 2014, 437:653-658.
100. Chen L., Wang Q., Wang G.D., et al. miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS Lett 2013, 587:1366-1372.
101. Osaki M., Takeshita F., Sugimoto Y., et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 2011, 19:1123-1130.
102. Wang Z., Xia Q., Cui J., et al. Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line. Oncol Rep 2014, 31:2720-2726.
103. Wallace GCt, Haar C.P., Vandergrift W.A., et al. Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol 2013, 114:43-50.
104. Mammoto T., Mukai M., Mammoto A., et al. Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett 2002, 184:165-170.
105. Ye Z., Jingzhong L., Yangbo L., et al. Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol Res 2014, 21:201-207.
106. Baccarani M., Castagnetti F., Gugliotta G., et al. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis 2014, 6:e2014005.
107. Mei Q., Li F., Quan H., et al. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci 2014, 105:755-762.
108. Yu H., Lu Y., Li Z., et al. microRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr Drug Targets 2014, 15:817-828.
109. Missiaglia E., Shepherd C.J., Patel S., et al. MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 2010, 102:1769-1777.
110. Nohata N., Hanazawa T., Enokida H., et al. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 2012, 3:9-21.
111. Shahab S.W., Matyunina L.V., Hill C.G., et al. The effects of MicroRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. BMC Med Genomics 2012, 5:33.
112. Hill C.G., Matyunina L.V., Walker D., et al. Transcriptional override: a regulatory network model of indirect responses to modulations in microRNA expression. BMC Syst Biol 2014, 8:36.
113. Babae N., Bourajjaj M., Liu Y., et al. Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget 2014, 5:6687-6700.